Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImExHSASX:IME 54 Price-to-Tangible-Book is 1.74 as of Sep. 14, 2026. GuruFocus rates ASX:IME with a GF Score™ of 54/100 and a GF Value™ of A$0.42 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 151 Medical Diagnostics & Research companies, ImExHS ranks better than 70.86% on this metric.
As of today (2026-09-14), ImExHS's share price is A$0.325. ImExHS's Tangible Book per Share of Jun. 2026 for the quarter that ended in Jun. 2026 was A$0.19. Hence, ImExHS's Price to Tangible Book Ratio of today is 1.74.
The historical rank and industry rank for ImExHS's Price-to-Tangible-Book or its related term are showing as below:
ASX:IME'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.71 Med: 3.09 Max: 15.61
Current: 1.71
During the past 13 years, ImExHS's highest Price to Tangible Book Ratio was 15.61. The lowest was 1.71. And the median was 3.09.
ASX:IME's Price-to-Tangible-Book is ranked better than 70.86% of 151
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.56
vs ASX:IME: 1.71
A closely related ratio is called PB Ratio. As of today, ImExHS's share price is A$0.325. ImExHS's Book Value per Sharefor the quarter that ended in Jun. 2026 was A$0.32. Hence, ImExHS's P/B Ratio of today is 1.03.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
ImExHS Price-to-Tangible-Book Related Terms
ImExHS Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for ImExHS's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IME vs TMO, DHR, NTRA: Price-to-Tangible-Book Comparison
For the Diagnostics & Research subindustry, ImExHS's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImExHS Price-to-Tangible-Book vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ImExHS's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where ImExHS's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
ImExHS (ASX:IME) has a Price-to-Tangible-Book of 1.74 as of Sep. 14, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on ImExHS and its competitors. According to the industry distribution chart, ImExHS ranks #44 out of 151 companies in the Medical Diagnostics & Research industry, placing it in the top 29.1%.
Is ImExHS's Price-to-Tangible-Book too high?
ImExHS's current Price-to-Tangible-Book is 1.74. The Medical Diagnostics & Research industry median Price-to-Tangible-Book is 2.56. ImExHS's value of 1.74 is 32% below this industry median. Based on the distribution chart, ImExHS ranks #44 out of 151 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, ImExHS has a GF Score™ of 54/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ImExHS's Price-to-Tangible-Book compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, ImExHS ranks #44 out of 151 companies for Price-to-Tangible-Book. This puts ImExHS in the upper half of its industry. The industry median Price-to-Tangible-Book is 2.56. ImExHS's value of 1.74 is 32% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Medical Diagnostics & Research company?
The median Price-to-Tangible-Book among Medical Diagnostics & Research companies is 2.56, based on 151 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ImExHS's current Price-to-Tangible-Book of 1.74 is 32% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on ImExHS and its competitors. For the Medical Diagnostics & Research industry, the median Price-to-Tangible-Book is 2.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ImExHS's current Price-to-Tangible-Book is 1.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImExHS stock overvalued right now?
Based on GuruFocus' analysis, ImExHS (ASX:IME) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.42, compared to a current price of A$0.33 — trading 22.6% below its estimated fair value. The current Price-to-Tangible-Book is 1.74 and 32% below the Medical Diagnostics & Research industry median of 2.56. ImExHS's overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For ImExHS (ASX:IME), the current Price-to-Tangible-Book is 1.74 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ImExHS (ASX:IME) Overvalued in 2026?
Based on GuruFocus' analysis, ImExHS stock appears to be undervalued.
The current stock price of A$0.33 is trading 22.6% below its estimated GF Value™ of A$0.42.
GuruFocus considers ImExHS to be Modestly Undervalued.
Key valuation signals for ASX:IME:
Price-to-Tangible-Book: 1.74
GF Value™: A$0.42 vs. price of A$0.33 (22.6% below fair value)
Industry Position: 32% below the Medical Diagnostics & Research median (#44 of 151)
No single metric tells the full story. See the ASX:IME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ImExHS Ltd is a healthcare technology company engaged in the provision of medical imaging software and radiology services. The company develops and delivers enterprise imaging solutions, including radiology information systems and picture archiving and communication systems, as well as provides diagnostic imaging and teleradiology services to healthcare institutions. The company operates through two reportable segments: Software, which focuses on the development and sale of imaging systems and platforms, and Radiology Services, which provides diagnostic and teleradiology services to hospitals and medical facilities. It generates the majority of its revenue from the Radiology segment.
54GF Score
Get the complete analysis for ASX:IME
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IME has been successfully added to your 
